BGLC BioNexus Gene Lab Corp.
Healthcare$2.07+2.73%ClosedMarket Cap: $4.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.60
P/S
0.76
EV/EBITDA
-0.11
DCF Value
$-13.18
FCF Yield
-29.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
13.5%
Operating Margin
-54.9%
Net Margin
-54.7%
ROE
-37.4%
ROA
-13.7%
ROIC
-14.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $22.8K | -99.5% | $-571.4K | $-543.6K | $— | — |
| Q4 null | $483.8K | -0.8% | $-1.0M | $-1.0M | $— | — |
| FY null | $7.4M | 14.6% | $-3.2M | $-3.0M | $— | — |
| Q3 null | $2.5M | 14.8% | $-702.5K | $-709.0K | $— | — |
| Q2 null | $2.3M | 16.3% | $-611.3K | $-616.2K | $— | — |
| Q1 null | $2.1M | 16.1% | $-618.4K | $-623.3K | $— | — |
| Q4 null | $2.5M | 12.3% | $-416.2K | $-348.3K | $— | — |
| FY null | $9.5M | 13.6% | $-1.6M | $-1.6M | $— | — |
| Q3 null | $2.6M | 12.4% | $-1.3M | $-1.3M | $— | — |
| Q2 null | $2.0M | 14.6% | $259.2K | $199.1K | $— | — |
| Q1 null | $2.4M | 15.3% | $-79.0K | $-103.8K | $— | — |
| Q4 2023 | $2.3M | 11.7% | $256.7K | $307.4K | $0.17 | — |